Researchers in Tayside and Lanarkshire are aiming to investigate the effects of the drug Benralizumab on airways, assessing whether it may help reduce inflammation in the airways of people with Chronic Obstructive Pulmonary Disease (COPD).
Who can take part?
To be eligible for this study, you must be aged between 40 and 85 years and have COPD that is not controlled by inhaled corticosteroids. If you agree to take part, you will receive either active medication (Benralizumab) or a dummy medication (placebo).
The study involves hospital visits for around 1-3 years. Initially, you'll receive medicine every 4 weeks. After 3 months you'll need to visit the clinic about every 8 weeks. During these visits, you'll be asked to donate blood and urine samples, check vital signs like heart rate and blood pressure, undergo a physical examination, have an ECG to measure your heart, and assessments to check your lungs.
Additionally, you'll be provided with an electronic diary to use twice a day at home, complete questionnaires about your COPD symptoms and how you're feeling.
If you would like to take part in this study, please get in touch with the SHARE Studies Team by telephone on 01382 383235 or email at [email protected] and we can tell you more about the study.
Also, if this study is not suitable for you, please register for SHARE so that we can let you know about other studies which may be relevant to you Register now.